Peptide Therapy Guides

The class of incretin-mimicking peptides that reshaped the landscape of metabolic medicine — and generated one of the most significant regulatory debates in modern pharmacy.

A synthetic pentadecapeptide derived from a gastric protein sequence, studied extensively in animal models for tissue repair — and removed from the FDA's 503A compounding list in late 2023.

A synthetic fragment of the naturally occurring protein thymosin beta-4, studied in preclinical models for its roles in tissue repair, angiogenesis, and anti-inflammatory signaling.

A selective growth hormone secretagogue of the GHRP class that stimulates pulsatile GH release from pituitary somatotrophs with a specificity profile distinct from other peptides in its family.

A long-acting synthetic GHRH analog engineered to bind albumin in the bloodstream, dramatically extending its half-life and producing sustained elevations in growth hormone and IGF-1 compared to native GHRH.

A naturally occurring copper-binding tripeptide with a fifty-year research history spanning wound healing, skin remodeling, and gene expression — used widely in cosmetics and studied for systemic regenerative applications.

A tetrapeptide synthesized from the amino acid composition of a bovine pineal extract, studied primarily by Russian researchers for telomerase activation and putative longevity effects — with an evidence base that is genuinely intriguing but substantially weaker than most agents in this guide.

The only peptide in this guide with FDA approval for a human indication — bremelanotide (Vyleesi) was approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder.